Steven Mah

Stock Analyst at TD Cowen

(2.23)
# 2,829
Out of 5,044 analysts
29
Total ratings
37.93%
Success rate
11.72%
Average return

Stocks Rated by Steven Mah

Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $32.21
Upside: +80.07%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28$31
Current: $27.54
Upside: +12.56%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280$120
Current: $12.19
Upside: +884.41%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $5.87
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $21.15
Upside: +98.58%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $5.62
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $1.47
Upside: +580.27%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $4.37
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39$21
Current: $2.42
Upside: +767.77%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150$155
Current: $192.81
Upside: -19.61%
Maintains: Overweight
Price Target: $135$140
Current: $22.73
Upside: +515.93%
Upgrades: Overweight
Price Target: $20$52
Current: $2.01
Upside: +2,487.06%
Upgrades: Overweight
Price Target: $340$415
Current: $95.03
Upside: +336.70%
Maintains: Overweight
Price Target: $168$250
Current: $27.94
Upside: +794.77%